Logo for ABIVAX Société Anonyme

ABIVAX Investor Relations Material

Latest events

Logo for ABIVAX Société Anonyme

H2 2023

ABIVAX
Logo for ABIVAX

H1 2024

9 Sep, 2024
Logo for ABIVAX

Corporate Presentation

15 Jul, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from ABIVAX Société Anonyme

Access all reports
ABIVAX Société Anonyme is a clinical-stage biotechnology company that focuses on developing therapeutics designed to modulate the body's natural immune regulatory mechanisms. The company is primarily engaged in advancing its lead drug candidate, obefazimod, which is currently undergoing clinical trials aimed at treating moderately to severely active ulcerative colitis. Additionally, ABIVAX is exploring obefazimod's potential in treating other chronic inflammatory diseases, including Crohn's disease, through ongoing clinical trials and research initiatives. The company is headquartered in Paris, France, and its shares are listed on both the Nasdaq and the Euronext Paris.